Our Mission

History

Our Leadership

• Our Team
• Our Board

Corporate Social Responsibility

Transparency Disclosure

Etigilimab (MPH-313)

Alvelestat (MPH-966)

Setrusumab (BPS-804)

Acumapimod (BCT-197)

Leflutrozole (BGS-649)

Navicixizumab (OMP-305B83)

Our Approach

Partnering Contact

Current Partnerships

Results, Reports and Presentations

NASDAQ

• Share Data
• SEC Filings
• Whistleblower Services

Investor Information

• Analyst Coverage
• Investor Contacts and Advisers
• FAQ
• Registrar Services
• Warning to Investors
• AIM Delisting
• Shareholder Meetings

Corporate Governance

• Division of Responsibilities
• Board Committees
• Relationships with Stakeholders and Shareholders
• Corporate Social Responsibility
• Key Documents
• Transparency Disclosure

US Tax

Register for Email Alerts

Events and Conferences

Press Releases

Transparency Disclosure

Our Business Model

Our Strategy